This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

As Hostile Takeover Bids Recede, Investors Bet on Earnings

Stocks in this article: GGC VMC ILMN MDRX

NEW YORK ( TheStreet) -- Just a few months ago, hostile bids for Georgia Gulf (GGC), Vulcan Materials (VMC) and Illumina (ILMN) seemed to be a savior for faltering shares. Takeovers now seem less likely to work, but investor reaction to stalled premium share bids has been muted.

For many C-suites looking at the prospect of a European meltdown, the U.S. "fiscal cliff" caused by a divided Congress, and a still lukewarm economic recovery, it's been a difficult nine months, but few companies had it harder than those that became the target of activist funds and hostile corporate bidders as their shares tumbled.

Now analyst forecasts and the investor reaction signal that as those bids recede, the prospect of earnings recoveries in coming years may outweigh the share jolt of an immediate deal.

Amid generally weak M&A markets and overall economic uncertainty, a string of unsolicited takeover offers such as Westlake Chemicals (WLK) $1.1 billion bid for Georgia Gulf, Martin Marietta's (MLM) near-$5 billion bid for Vulcan Materials and Roche's $6.8 billion offer for Illumina -- in addition to a flurry of activist campaigns waged by Carl Icahn on Commercial Metals (CMC), Oshkosh (OSK) and CVR Energy (CVI) -- have given many investors and corporate executives a tough choice: Sell now at a premium to battered share prices or draw up plans to capture an economic or business cycle recovery?

In the case of most of those bids, and recent unsolicited offers by for Avon Products (AVP) and Human Genome Sciences (HGSI), management seems to favor gutting it out independently. While the verdicts still loom for Avon Products and Human Genome Sciences, among others, recent shareholder votes and analyst forecasts indicate more excitement about the long-term stock earnings of some companies in hostile crosshairs than the immediate gain of a sale.

On Friday, a Delaware court delayed Martin Marietta's bid for Vulcan Materials by four months and beyond the company's June annual shareholder meeting where a slate of hostile Martin Marietta directors had been nominated to Vulcan's board. In reaction, Wells Fargo analyst Adam Rudiger noted that shares of Vulcan were unlikely to fall back to a share price in the mid $30s before a hostile bid emerged in 2011 because of the company's progress in cutting costs, and improving margins in its construction aggregates business to go with generally improving earnings.

If Vulcan Materials shares trade down significantly below $35, we believe they would be attractive to long-term investors, all else being equal," adds Rudiger, who notes that nearly $500 million in planned asset sales can help the company's debt fall to more sustainable levels. Meanwhile, the key to any deal may hinge on regulatory approvals from the antitrust division of the Department of Justice.

"This is a setback for MLM, but in our view the coming decision of the DOJ on the assets that need to be divested remains the key decision," wrote Jefferies analysts Mike Betts in a Monday note to clients. Betts gives Vulcan shares a buy rating and a $61 a share price target. Rudiger of Wells Fargo gives shares a market perform rating and a $41 to $42 a share price target.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs